Alumis sends material breach notice to Climb Bio over $3M milestone; Climb Bio files declaratory judgment action

ALUMIS INC.

Climb Bio failed to pay $3,000,000 Development Milestone due Jan 1, 2026 under the Asset Purchase Agreement.
Climb Bio filed a declaratory judgment action in Delaware Superior Court on Dec 31, 2025 claiming budoprutug is not a 'Product' under the APA.
Alumis intends to seek the $3M milestone payment, interest, indemnification for attorneys' fees and costs.
Total milestone payments under APA could reach $157.5M plus royalties and sublicense income per Climb Bio's SEC filings.
Alumis believes Climb Bio's position is contrary to the plain terms and intent of the APA and prior statements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.